(HealthDay News) — The U.S. Food and Drug Administration on Monday expanded its approval for the Optune device to include newly diagnosed glioblastoma multiforme. Optune involves placing electrodes on ...

ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure (NASDAQ:NVCR) announced today results from a retrospective post-hoc analysis of its phase 3 pivotal EF-14 trial data showing that increased compliance ...

Jeffrey Weiss is fitted with an Optune device as part of his treatment for glioblastoma at his home in North Dallas on April 12. Louis DeLuca / Staff Photographer I'm now more than six months into the ...

ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure (NASDAQ:NVCR) announced today that the Japanese Ministry of Health, Labour and Welfare has approved the recommendation by Japan’s Central Social Insurance ...

As a particularly aggressive brain tumor, it almost goes without saying that glioblastomas are scary things. Fortunately, patients are benefiting from a new technology that has only been available to ...

Please provide your email address to receive an email when new articles are posted on . A wearable medical device designed to deliver alternating electrical fields administered in addition to ...

Novocure released clinical trial data at the American Society of Clinical Oncology meeting showing that its cancer-fighting Optune device improves survival in newly diagnosed brain cancer patients, ...

Novocure has received approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for the use of its portable Optune Lua device alongside PD-1/PD-L1 inhibitors to treat non-small cell lung ...

A wearable device that uses electricity to disrupt cancer cells has improved survival for people with brain cancer for the first time in more than a decade. Joyce Endresen often gets asked what is on ...

CHICAGO — A medical device made by Novocure that creates electric fields in the lungs via wearable skin patches extended the survival of patients with lung cancer in a clinical trial, researchers ...